Clinical Trials - August 23, 2021
AstraZeneca discontinues CHAMPION-ALS trial
Alexion, AstraZeneca Rare Disease, is discontinuing CHAMPION-ALS, the global Phase III clinical trial of Ultomiris (ravulizumab) in adults with amyotrophic lateral sclerosis (ALS). Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. “We are disappointed by this outcome and what it means […]
Acquisition - December 14, 2020
AstraZeneca to acquire Alexion in USD 39 billion deal
AstraZeneca and Alexion Pharmaceuticals have entered into a definitive agreement for AstraZeneca to acquire Alexion. Alexion shareholders will receive USD 60 in cash and 2.1243 AstraZeneca American Depositary Shares (ADSs) (each ADS representing one-half of one (1/2) ordinary share of AstraZeneca, as evidenced by American Depositary Receipts (ADRs)) for each Alexion share. Based on AstraZeneca’s […]
Agreement - March 20, 2019
Affibody announces co-development agreement with Alexion
Swedish Affibody and US Alexion Pharmaceuticals have announced a partnership to co-develop ABY-039 for rare Immunoglobulin G (IgG)-mediated autoimmune diseases. Under the terms of the agreement, Alexion will provide Affibody with an upfront payment of $25 million, with the potential for additional development- and sales-based milestones of up to $625 million and tiered low double-digit […]
